We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$58.2M
Cap. Flow %
-7.45%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Miscellaneous 84.33%
2 Healthcare 15.04%
3 Consumer Staples 0.29%
4 Technology 0.14%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNBX
126
DELISTED
BNB PLUS CORP
BNBX
– –
0
– -$349K
ATEC icon
127
Alphatec Holdings
ATEC
$1.65B
– –
-94,216
Closed -$281K
AZN icon
128
AstraZeneca
AZN
$252B
– –
-34,232
Closed -$2.59M
BIIB icon
129
CALL
Biogen
BIIB
$31.8B
– –
-30
Closed -$871K
CANF
130
Can-Fite BioPharma American Depositary Shares
CANF
$4.86M
– –
-37
Closed -$130K
BGMS
131
Bio Green Med Solution Inc
BGMS
$7.02M
– –
0
– -$36K
ESPR
132
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-370
Closed -$1.45M
FCEL icon
133
FuelCell Energy
FCEL
$1.21B
– –
-84
Closed -$36.3K
GALT icon
134
Galectin Therapeutics
GALT
$366M
– –
-14,029
Closed -$89K
INCY icon
135
Incyte
INCY
$24.6B
– –
-41,419
Closed -$2.77M
INCY icon
136
PUT
Incyte
INCY
$24.6B
– –
-406
Closed -$2.72M
KZR
137
DELISTED
Kezar Life Sciences
KZR
– –
-4,251
Closed -$735K
NGNE icon
138
Neurogene
NGNE
$672M
– –
-2,760
Closed -$146K
NGNE icon
139
PUT
Neurogene
NGNE
$672M
– –
-23
Closed -$121K
NVO
140
CALL
Novo Nordisk
NVO
$188B
– –
-7,944
Closed -$18.3M
NVO
141
Novo Nordisk
NVO
$188B
– –
-858,710
Closed -$19.8M
NVO
142
PUT
Novo Nordisk
NVO
$188B
– –
-12,442
Closed -$28.7M
PAVM icon
143
PAVmed
PAVM
$41.8M
– –
-3,109
Closed -$1.33M
PHIO icon
144
Phio Pharmaceuticals
PHIO
$11.8M
– –
-28
Closed -$325K
SGMO
145
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-878
Closed -$1.25M
SSKN
146
DELISTED
Strata Skin Sciences
SSKN
– –
-168,228
Closed -$3.45M
XTIA icon
147
XTI Aerospace
XTIA
$36.5M
– –
0
– -$273K
TRAW icon
148
Traws Pharma
TRAW
$8.12M
– –
-11
Closed -$26K
ARAV
149
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-36,767
Closed -$447K
CYTO
150
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-33
Closed -$206K
3 4 5
6
7

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $58.2M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 84% of assets, up from 73% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.